undefined(BK1576)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1576

0.000

+0.000

--

最高0.000	最低0.000	成交量0.00
今开0.000	昨收0.000	日振幅0.00%
总市值0.00	流通市值0.00	总股本0.00
成交额0.00	换手率--	流通股本0.00
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1576","market":"HK","secType":"PLATE","latestPrice":0,"timestamp":0,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatusCode":0,"change":0,"open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"adr":0,"adjPreClose":0},"requestUrl":"/m/hq/s/BK1576/tweets","defaultTab":"tweets","newsList":[{"id":"2486015625","title":"药明康德：胡正国11月21日减持8.11万股，涉资404.92万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2486015625","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486015625?lang=zh_cn&edition=full","pubTime":"2024-11-26 11:30","pubTimestamp":1732591805,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1576","LU0320764599.SGD","LU2125910500.SGD","BK1141","BK1583","LU1997245177.USD","02359","LU1997245094.SGD","LU0052750758.USD","603259","LU0708995583.HKD","LU2488822045.USD","LU2242644610.SGD","LU0456842615.SGD","LU2045819591.USD","LU1046422090.SGD","BK0216"],"gpt_icon":0},{"id":"2486090172","title":"维亚生物盘中异动 早盘股价大涨8.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486090172","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486090172?lang=zh_cn&edition=full","pubTime":"2024-11-26 10:26","pubTimestamp":1732587998,"startTime":"0","endTime":"0","summary":"2024年11月26日早盘10时26分，维亚生物股票出现异动，股价大幅上涨8.54%。截至发稿，该股报0.890港元/股，成交量31.4万股，换手率0.01%，振幅8.54%。维亚生物股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，圣诺医药-B、华康生物医学、维亚生物涨幅较大，振幅较大的相关个股有博安生物、北海康成-B、维亚生物，振幅分别为26.12%、21.62%、8.54%。维亚生物公司简介：维亚生物科技控股集团是一家中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126102638abdf4fba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126102638abdf4fba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","01873"],"gpt_icon":0},{"id":"2486091695","title":"金斯瑞生物科技11月25日获南向资金加仓416.80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2486091695","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486091695?lang=zh_cn&edition=full","pubTime":"2024-11-26 09:30","pubTimestamp":1732584612,"startTime":"0","endTime":"0","summary":"11月25日, 南向资金增持金斯瑞生物科技416.80万股，连续4日增持。截止当日收盘，港股通共持有金斯瑞生物科技52900.44万股，占流通股24.74%。金斯瑞生物科技近5个交易日下跌3.56%，港股通累计增持1902.08万股；近20个交易日下跌16.96%，港股通累计增持3725.89万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126093143abdf2c06&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241126093143abdf2c06&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000320264.USD","BK1583","01548","BK1141","BK1576","HK0000306701.USD","HK0000306685.HKD","HK0000320223.HKD"],"gpt_icon":0},{"id":"2486070448","title":"乐普医疗(300003.SZ)：MWN105注射液、MWN109注射液获药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486070448","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486070448?lang=zh_cn&edition=full","pubTime":"2024-11-25 18:54","pubTimestamp":1732532092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，乐普医疗(300003.SZ)公告，公司控股子公司上海民为生物技术有限公司(简称“民为生物”)收到国家药品监督管理局(NMPA)核准签发的《药物临床试验批准通知书》，由民为生物申报的MWN109注射液、MWN105注射液临床试验申请获得批准。根据公告所示，MWN105注射液适应症为：超重或肥胖适应症、2型糖尿病;MWN109注射液适应症为：2型糖尿病、超重或肥胖适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215528.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0196","BK1583","BK0251","BK0201","BK1576","300003","03347","BK0113","BK0114","BK0042","BK1141","BK0188","BK0028"],"gpt_icon":0},{"id":"2486709868","title":"来自武汉的“翰思艾泰-B”首次递表，泰格医药、贝达药业、金斯瑞均有参投","url":"https://stock-news.laohu8.com/highlight/detail?id=2486709868","media":"活报告","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486709868?lang=zh_cn&edition=full","pubTime":"2024-11-25 18:14","pubTimestamp":1732529640,"startTime":"0","endTime":"0","summary":"LiveReport获悉，来自武汉的翰思艾泰生物医药科技（武汉）股份有限公司于2024年11月24日在港交所递交上市申请，拟香港主板上市，这是该公司第1次递交上市申请，独家保荐人为工银国际。截至最后实际可行日期，正在澳大利亚启动用于治疗晚期实体瘤恶性肿瘤的I/IIa期临床研究，并取得国家药监局就其在中国的临床研究的受理通知。截至2024年6月30日，公司账上现金1.5亿元。预计2031年全球肿瘤免疫疗法市场将占全球肿瘤药物市场份额的50.6%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/cj/2024-11-25/doc-incxhqmk8163822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1583","03347","BK0028","300347","300558","BK0216","BK1576","BK0077","BK0239","LU1820825898.SGD","BK0174","LU1146622755.USD","BK1141","BK0060"],"gpt_icon":0},{"id":"2486709366","title":"上海医药：I048临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486709366","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486709366?lang=zh_cn&edition=full","pubTime":"2024-11-25 18:03","pubTimestamp":1732529037,"startTime":"0","endTime":"0","summary":"南方财经11月25日电，上海医药公告，公司开发的I048临床试验申请获得国家药监局受理。I048是小分子一类新药，拟用于治疗精神分裂症。公司主导I048研发，拥有全球独占实施许可权益。截至目前，全球未有完全相同靶点和同适应症的药品上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411253249894789.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02607","BK1141","BK1197","03347","BK1583","BK1576"],"gpt_icon":0},{"id":"2486705687","title":"科伦药业(002422.SZ)子公司SKB501新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705687","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705687?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:45","pubTimestamp":1732527959,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦药业(002422.SZ)公告，公司近日获悉，公司控股子公司四川科伦博泰生物医药股份有限公司(简称“科伦博泰”)已于2024年11月25日收到国家药品监督管理局同意其开发的创新药物SKB501临床试验申请的临床试验通知书。SKB501是一款由科伦博泰针对靶点生物学特点，利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物，在临床前研究中显示出良好的疗效和安全窗，拟用于治疗晚期实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215436.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","LU1064131003.USD","BK1576","BK0239","BK0060","LU1064130708.USD","LU2148510915.USD","BK1583","03347","002422"],"gpt_icon":0},{"id":"2486549705","title":"上海医药(02607)：I048临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486549705","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486549705?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:42","pubTimestamp":1732527778,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(02607)发布公告，近日，上海医药集团股份有限公司(以下简称“上海医药”或“公司”)开发的I048(以下简称“该项目”)临床试验申请获得国家药品监督管理局(以下简称“国家药监局”)受理。I048是小分子一类新药，拟用于治疗精神分裂症。临床前研究显示在动物疾病模型上起到显著的治疗作用。该项目由上海医药主导研发，公司拥有全球独占实施许可权益。截至本公告披露日，该项目已累计投入研发费用2223.94万元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0099","BK0188","BK0196","03347","BK1141","601607","BK0020","BK0175","BK0028","BK0209","BK0187","BK0183","BK0184","BK1197","BK1583","BK0097","BK0012","BK1576","02607"],"gpt_icon":0},{"id":"2486970568","title":"上海医药最新公告：I048临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486970568","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486970568?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:41","pubTimestamp":1732527677,"startTime":"0","endTime":"0","summary":"上海医药公告，公司开发的I048临床试验申请获得国家药监局受理。I048是小分子一类新药，拟用于治疗精神分裂症。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500024668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["02607","BK1197","BK0183","BK0175","BK0188","BK0012","BK0028","BK0196","601607","BK0209","BK0099","BK0020","BK0097","BK0184","03347","BK0187","BK1576","BK1583","BK1141"],"gpt_icon":0},{"id":"2486668705","title":"科伦药业最新公告：子公司SKB501新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486668705","media":"证券之星","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486668705?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:40","pubTimestamp":1732527655,"startTime":"0","endTime":"0","summary":"科伦药业公告，公司控股子公司科伦博泰开发的创新药物SKB501的临床试验申请已获国家药品监督管理局批准。SKB501是一款利用OptiDCTM平台技术研发的新型ADC药物，具有自主知识产权，拟用于治疗晚期实体瘤。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500024665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","03347","BK1576","BK1583","BK1141","LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0239","002422"],"gpt_icon":0},{"id":"2486705542","title":"上海医药(601607.SH)：I048临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705542","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705542?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:40","pubTimestamp":1732527650,"startTime":"0","endTime":"0","summary":"智通财经APP讯，上海医药(601607.SH)发布公告，公司开发的I048临床试验申请获得国家药品监督管理局受理，I048是小分子一类新药，拟用于治疗精神分裂症。临床前研究显示在动物疾病模型上起到显著的治疗作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215425.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0187","BK0099","02607","BK0183","BK1583","BK1576","BK1197","BK0175","BK0196","BK0188","BK0020","03347","BK0184","BK0028","BK1141","BK0012","BK0097","BK0209","601607"],"gpt_icon":0},{"id":"2486703267","title":"康泰生物最新公告：20价肺炎球菌多糖结合疫苗开启Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2486703267","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486703267?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:29","pubTimestamp":1732526986,"startTime":"0","endTime":"0","summary":"康泰生物公告，全资子公司民海生物研发的20价肺炎球菌多糖结合疫苗已完成Ⅰ期临床试验准备工作，开启Ⅰ期临床试验，且近日已成功完成首例受试者入组。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500024524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03347","BK1576","300601","BK0201","BK0046","BK1583","BK1141","159646","BK0239"],"gpt_icon":0},{"id":"2486703811","title":"康泰生物(300601.SZ)：20价肺炎球菌多糖结合疫苗开启Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2486703811","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486703811?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:23","pubTimestamp":1732526603,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司全资子公司北京民海生物科技有限公司(简称“民海生物”)研发的20价肺炎球菌多糖结合疫苗已完成Ⅰ期临床试验准备工作，开启Ⅰ期临床试验，并于近日成功完成首例受试者入组。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215408.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK1141","159646","BK1576","BK0046","300601","03347","BK1583","BK0201"],"gpt_icon":0},{"id":"2486550703","title":"康泰生物最新公告：全资子公司民海生物研发的麻腮风联合减毒活疫苗开启Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2486550703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486550703?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:21","pubTimestamp":1732526506,"startTime":"0","endTime":"0","summary":"康泰生物公告，全资子公司民海生物研发的麻腮风联合减毒活疫苗已完成Ⅰ期临床试验准备工作，并成功完成首例受试者入组。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500023451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1583","BK1141","BK0046","BK0239","300601","03347","BK1576","BK0201"],"gpt_icon":0},{"id":"2486270874","title":"康泰生物(300601.SZ)：麻腮风联合减毒活疫苗开启Ⅰ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2486270874","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486270874?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:20","pubTimestamp":1732526451,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康泰生物(300601.SZ)公告，公司全资子公司北京民海生物科技有限公司(简称“民海生物”)研发的麻腮风联合减毒活疫苗已完成Ⅰ期临床试验准备工作，开启Ⅰ期临床试验，并于近日成功完成首例受试者入组。麻腮风联合减毒活疫苗是采用麻疹病毒减毒株、腮腺炎病毒减毒株和风疹病毒减毒株制备的联苗。该疫苗适用于8月龄以上的麻疹、腮腺炎和风疹易感者人群，接种后可刺激机体产生抗麻疹病毒、腮腺炎病毒和风疹病毒的免疫力，用于预防麻疹、流行性腮腺炎和风疹。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215404.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","BK1576","BK0239","BK0201","BK0046","300601","03347","BK1583"],"gpt_icon":0},{"id":"2486708545","title":"【港股通】科伦博泰生物(06990)创新药物SKB501获批临床试验 拟用于治疗晚期实体瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2486708545","media":"金吾财讯","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486708545?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:11","pubTimestamp":1732525886,"startTime":"0","endTime":"0","summary":"金吾财讯 | 科伦博泰生物(06990)公布，公司已于2024年11月25日收到国家药品监督管理局药品审评中心，同意公司开发的创新药物SKB501新药临床试验申请的临床试验通知书。SKB501是一款由公司针对靶点生物学特点，利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物，在临床前研究中显示出良好的疗效和安全窗，拟用于治疗晚期实体瘤。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MTU2NzYxOTI1Mjg5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1948364","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","03347","HSCEI","BK1583","BK1574","HSTECH","BK1141","159992","06990","BK1576","LU0196878994.USD","YANG","06978"],"gpt_icon":0},{"id":"2486707327","title":"科伦博泰生物-B(06990)：SKB501新药临床试验申请获国家药品监督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486707327","media":"智通财经","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486707327?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:08","pubTimestamp":1732525702,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，公司已于2024年11月25日收到国家药品监督管理局药品审评中心同意公司开发的创新药物SKB501新药临床试验申请的临床试验通知书。SKB501是一款由公司针对靶点生物学特点，利用OptiDCTM平台技术研发的具有自主知识产权的新型ADC药物，在临床前研究中显示出良好的疗效和安全窗，拟用于治疗晚期实体瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215383.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1141","06990","LU0196878994.USD","BK1576","03347","BK1583","BK1161"],"gpt_icon":0},{"id":"2486772550","title":"人福医药最新公告：玉蚕颗粒获得药物临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2486772550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486772550?lang=zh_cn&edition=full","pubTime":"2024-11-25 16:15","pubTimestamp":1732522514,"startTime":"0","endTime":"0","summary":"人福医药公告，全资子公司创新药研发中心近日收到国家药品监督管理局核准签发的玉蚕颗粒的《药物临床试验批准通知书》。玉蚕颗粒功能主治为补脾益肾，活血利水，用于脾肾气虚、湿瘀阻络证糖尿病肾脏疾病蛋白尿的治疗。该药品由创新药研发中心和上海复活石医药科技有限公司联合开发及申报，累计研发投入约为900万元人民币。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112500019639.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0096","BK0239","BK1583","BK0188","BK0012","600079","BK0070","BK1141","BK1576","BK0185","03347"],"gpt_icon":0},{"id":"2486776261","title":"人福医药(600079.SH)：玉蚕颗粒获得药物临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2486776261","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486776261?lang=zh_cn&edition=full","pubTime":"2024-11-25 15:33","pubTimestamp":1732520032,"startTime":"0","endTime":"0","summary":"智通财经APP讯，人福医药 发布公告，公司全资子公司武汉人福创新药物研发中心有限公司近日收到国家药品监督管理局核准签发的玉蚕颗粒的《药物临床试验批准通知书》。玉蚕颗粒由创新药研发中心和上海复活石医药科技有限公司联合开发及申报，根据双方签订的合同，该项目的所有技术成果及各项知识产权由创新药研发中心独家所有。截至目前，玉蚕颗粒项目的累计研发投入约为900万元人民币。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1215280.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0185","BK1583","BK1576","BK0012","BK0028","BK0096","BK0070","03347","600079","BK0188","BK1141","BK0239"],"gpt_icon":0},{"id":"2486372701","title":"翰思艾泰-B，来自湖北武汉，递交IPO招股书，拟赴香港上市，工银国际独家保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2486372701","media":"瑞恩资本Ryanbe...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486372701?lang=zh_cn&edition=full","pubTime":"2024-11-25 13:52","pubTimestamp":1732513920,"startTime":"0","endTime":"0","summary":"2024年11月24日，来自湖北武汉的翰思艾泰生物科技(武汉)股份有限公司Hanx Biopharmaceuticals  Co., Ltd.在港交所递交招股书，拟香港主板IPO上市。翰思艾泰的核心产品HX009是一种自主研发的PD-1/SIRPα双功能抗体融合蛋白，目前已在澳大利亚及中国完成HX009的I期临床试验。翰思艾泰已完成根据国家药监局批准对HX301进行的I期临床研究，并计划开展HX301与替莫唑胺联用治疗脑胶质母细胞瘤的II期临床研究。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2024-11-25/doc-incxhcvq8260278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HK0000320264.USD","BK0277","BK0174","01548","LU1146622755.USD","HK0000306685.HKD","BK1141","BK0077","LU1820825898.SGD","HK0000320223.HKD","BK1576","BK0239","BK0086","BK0075","BK1583","300347","HK0000306701.USD","600133","BK0028","300558","BK0102","BK0216","BK0060"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0217},{"period":"1month","weight":-0.0699},{"period":"3month","weight":0.0714},{"period":"6month","weight":0.0365},{"period":"1year","weight":0.0906},{"period":"ytd","weight":0.1234}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1576","nameEN":"BK1576"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"undefined(BK1576)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供undefined(BK1576)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":",BK1576,股票,股票老虎,股票老虎国际,行情,股票行情,股价,股市,股票价格,股票交易,股票购买,股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"undefined(BK1576)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供undefined(BK1576)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}